🔗 Share this article

A shadow market for unapproved slimming medications is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.

Investigational Treatment Acquiring Traction Via Social Media

Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its alleged fat-burning effects. Followers are urged to message these profiles directly for source information, while also obtaining discount codes.

Active Trade on Messaging Platforms

Separately, a flourishing trade exists on messaging services, where communities with thousands of participants share comparison images, administration instructions and assertions of next-day UK delivery. Vendors market the drug there before redirecting buyers to WhatsApp for transactions.

Understanding Retatrutide

Retatrutide is an experimental injection created by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies indicate it could assist patients reduce up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being promoted online as the successor to Ozempic.

Healthcare Professionals Express Concerns

Nevertheless, physicians and pharmacists have warned that the distribution of what is still an unlicensed drug in the United Kingdom is a cause for concern and could lead to individuals administering products of uncertain source.

Several experts said the demand for the experimental drug could be connected to the increasing cost of licensed weight loss treatments such as Mounjaro.

Legal Position and Implementation

Selling retatrutide on TikTok or messaging apps is prohibited in the United Kingdom, as it is an unapproved drug that cannot be promoted or distributed for personal consumption under the Human Medicines Regulations 2012.

Several content creators attempt to sidestep the rules by calling to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but promotion and distribution can still breach medicines, marketing, and consumer regulations, potentially leading to penalties, prosecution or imprisonment.

Platform Response and Content Removal

According to TikTok, the service has taken down problematic content and banned related keywords and query recommendations. The organization stated it was dedicated to keeping the service secure and investing in strengthening compliance measures.

Digital Trading Operations

Research also found groups with up to nine thousand participants marketing the experimental drug using the platform's integrated discovery tool, which operates like a public directory. Typing “retatrutide” immediately displays groups with thousands of users, filled with images of slimming results, positive reviews and detailed guides for mixing or administering at residence.

Within minutes of joining one community, a seller posted contact information, where most purchases occur. The seller sent an instruction manual and guaranteed delivery within 48 hours. When asked whether the product was authentic, one vendor responded: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. Not one inquired about body mass, health issues or previous experience.

Item Details and Pricing

Within these groups, messages display black plastic packages with Royal Mail labels, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, prepared at residence with purified liquid, or ready-to-use pens usually sold at £160 for 20mg. When asked how much time a injector should last, sellers give contradictory responses varying between a several days to “depends on your body”.

Platform Moderation and Safety Actions

A spokesperson for Telegram stated it regularly moderated dangerous material on its platform including material that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Medical Expert Warnings

“People are injecting substances they can’t verify. Although the research behind retatrutide is valid, these digital products may not include what they advertise,” stated a pharmacy expert, the director of pharmaceutical services at Chemist4U.

A medical professional of an online medical service connected the increase in interest to current price rises for approved slimming medications such as Mounjaro. “With costs rising, patients are turning to online platforms. But counterfeit treatments are extremely dangerous. You can’t be certain what’s contained or whether the conditions they were made in was clean,” she explained.

Her staff has already encountered patients harmed by self-injection from unverified suppliers. “We understand the frustration, but buying from messaging apps or WhatsApp is taking chances with your well-being,” said the doctor. “These materials could be impure or incorrectly dosed.”

Producer Statement

A spokesperson from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any regulatory agency globally. “Therefore at this point no one can sell [it] for human use,” they said, adding that any item “misleadingly claiming itself as a company investigational product not yet authorized … may subject patients to possibly serious health risks”.